|By PR Newswire||
|December 16, 2013 08:01 AM EST||
LONDON, December 16, 2013 /PRNewswire/ --
On Friday, December 13, 2013, the U.S. equity market fluctuated between gains and losses. The S&P 500 ended the day at 1,775.32, down 0.01%; the Dow Jones Industrial Average closed at 15,755.36, up 0.10%; and the NASDAQ Composite finished at 4,000.98, up 0.06%. The S&P 500 Health Care Sector Index closed the session at 621.05, up 0.04%; and the same has gained 4.22% in the previous three months, underperforming the S&P 500, which has gained 4.58% during the same period. The major movers in the sector included Dendreon Corp. (NASDAQ: DNDN), Stryker Corp. (NYSE: SYK), Novartis AG (NYSE: NVS), and Repros Therapeutics Inc. (NASDAQ: RPRX). All these companies are tracked by AAAResearchReports.com. Download free technical analysis and charting reports on DNDN, SYK, NVS, and RPRX now at:
Dendreon Corp.'s stock surged on Friday, even as the US equity market fluctuated between gains and losses. The company's shares finished the day 3.27% higher at $3.32, after oscillating between $3.20 and $3.34 during the trading session. A total of 4.21 million shares were traded, which is below the daily average volume of 4.32 million. The company's shares have surged 30.51% in the previous one month and 11.99% in the last three trading sessions, compared to a loss of 1.27% and 1.51% in the S&P 500 during the respective periods. Additionally, Dendreon Corp.'s stock is trading above its 50-day moving average of $2.71. Download free research on DNDN today by registering at:
Shares in Stryker Corp. ended the day at $71.56, down 0.39%, after fluctuating between $71.22 and $72.15 during Friday's trading session. A total of 2.08 million shares were traded, which is below the daily average volume of 1.34 million. The company's shares have advanced 2.05% in the previous three months, underperforming the S&P 500, which has gained 4.58% during the same period. However, Stryker Corp.'s stock is trading above its 200-day moving average of $68.82. Sign up and have access to our free report on SYK at:
On Friday, Novartis AG's stock closed the day at $76.84, up 0.27% from the previous day's closing price of $76.63. The company's shares vacillated between $76.44 and $77.00 during the trading session. A total of 0.68 million shares were traded, which is below the daily average volume of 1.30 million. The company's shares have gained 0.84% in the previous three months, underperforming the S&P 500, which has gained 4.58% during the same period. Further, Novartis AG's stock is trading above its 200-day moving average of $73.99. Sign up and read the complimentary report on NVS at:
Repros Therapeutics Inc.'s stock rose 2.38% on Friday, closing the day's session at $17.18, after vacillating between $16.55 and $17.35 during the trading session. A total of 0.28 million shares were traded, which is below the daily average volume of 0.74 million. The company's shares have gained 1.12% in the previous three trading sessions and 13.70% in the last one month compared to a loss of 1.51% and 1.27% in the S&P 500 during the respective periods. However, Repros Therapeutics Inc.'s stock is trading below its 50-day and 200-day moving averages of $18.51 and $18.47, respectively. The free report on RPRX can be downloaded by signing up now at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE AAA Research Reports